Insider Selling: uniQure (NASDAQ:QURE) CEO Sells 14,581 Shares of Stock

Key Points

• CEO Matthew Kapusta sold 14,581 shares on March 4 at an average price of $9.06 (about $132,104), trimming his stake by 2.16% to 660,658 shares.
• Regulatory setback: A senior FDA official called uniQure’s Huntington’s disease therapy unsuccessful and the agency requested a new randomized, placebo‑controlled study, spurring a roughly 32% one‑week stock plunge and multiple class‑action notices.
• Market and analyst reaction: The stock has seen extreme volatility and heavy volume, mixed analyst coverage (average rating "Hold" with a $34.33 target), and institutional investors hold about 78.8% of the shares.

uniQure N.V. (NASDAQ:QURE - Get Free Report) CEO Matthew Kapusta sold 14,581 shares of the firm's stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $9.06, for a total value of $132,103.86. Following the sale, the chief executive officer owned 660,658 shares in the company, valued at $5,985,561.48. This trade represents a 2.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

uniQure Price Performance

NASDAQ QURE traded up $3.62 during trading hours on Friday, reaching $14.27. The company's stock had a trading volume of 16,602,429 shares, compared to its average volume of 3,442,688. The firm has a market capitalization of $892.30 million, a price-to-earnings ratio of -4.14 and a beta of 0.73. The company's 50-day moving average is $22.25 and its two-hundred day moving average is $29.44. The company has a debt-to-equity ratio of 0.25, a current ratio of 10.43 and a quick ratio of 7.12. uniQure N.V. has a 1-year low of $7.76 and a 1-year high of $71.50.

uniQure (NASDAQ:QURE - Get Free Report) last issued its quarterly earnings data on Monday, March 2nd. The biotechnology company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.93) by $0.37. uniQure had a negative return on equity of 174.03% and a negative net margin of 1,236.00%.The company had revenue of $5.57 million for the quarter, compared to analyst estimates of $4.84 million. On average, equities analysts predict that uniQure N.V. will post -3.75 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on QURE. HC Wainwright reaffirmed a "buy" rating and issued a $70.00 target price on shares of uniQure in a research note on Tuesday, February 10th. The Goldman Sachs Group decreased their target price on shares of uniQure from $37.00 to $9.00 and set a "neutral" rating on the stock in a report on Tuesday. Barclays started coverage on uniQure in a research report on Tuesday, January 27th. They issued an "equal weight" rating and a $31.00 price objective for the company. TD Cowen reiterated a "buy" rating on shares of uniQure in a report on Tuesday. Finally, Wolfe Research initiated coverage on shares of uniQure in a research note on Monday, February 23rd. They issued a "peer perform" rating on the stock. Seven research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $34.33.

Hedge Funds Weigh In On uniQure

A number of institutional investors and hedge funds have recently modified their holdings of QURE. Private Trust Co. NA acquired a new stake in shares of uniQure during the 3rd quarter worth about $28,000. Jones Financial Companies Lllp increased its position in shares of uniQure by 509.0% during the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company's stock worth $33,000 after purchasing an additional 509 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in shares of uniQure by 5.5% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,150 shares of the biotechnology company's stock valued at $243,000 after purchasing an additional 533 shares during the last quarter. Arizona State Retirement System lifted its holdings in shares of uniQure by 6.0% in the 4th quarter. Arizona State Retirement System now owns 11,141 shares of the biotechnology company's stock valued at $267,000 after purchasing an additional 627 shares during the last quarter. Finally, Ensign Peak Advisors Inc grew its stake in uniQure by 21.7% during the 4th quarter. Ensign Peak Advisors Inc now owns 3,650 shares of the biotechnology company's stock worth $87,000 after buying an additional 650 shares during the last quarter. Institutional investors and hedge funds own 78.83% of the company's stock.

uniQure News Summary

Here are the key news stories impacting uniQure this week:

• Neutral Sentiment: Mizuho issued a neutral rating on QURE, keeping some analyst coverage tepid rather than bullish. Read More.
• Negative Sentiment: A senior FDA official publicly called uniQure’s Huntington’s disease therapy unsuccessful and defended the agency’s call for a new randomized, placebo‑controlled study — a move that raises the likelihood of delays and additional trials before any BLA. Read More.
• Negative Sentiment: Broad media coverage amplifies regulatory risk: multiple outlets (WSJ, CNBC, FierceBiotech, BioSpace) report public rebukes from FDA/HHS and intensifying back‑and‑forth with uniQure — increasing reputational and approval uncertainty. Read More.
• Negative Sentiment: Numerous class‑action and shareholder‑lawsuit notices filed and circulated by law firms (lead‑plaintiff deadline April 13, 2026) — these raise potential legal liability, management distraction, and ongoing downward pressure on the share price. Read More.
• Negative Sentiment: Analyst actions have turned negative: Chardan cut its price target and other outlets report pessimistic forecasts (Goldman Sachs coverage noted), contributing to recent downgrades and reduced sell‑side enthusiasm. Read More.
• Negative Sentiment: Multiple insiders (including the CEO and CFO) sold shares on March 4 at ~$9.06 — the CEO, CFO and other insiders reduced holdings by low single‑digit to ~5% amounts. Insider selling can be perceived negatively by the market even though insiders still hold large positions. Read More.
• Negative Sentiment: Short‑term price shock: Zacks and other outlets report the stock plunged ~32% in a week after the FDA said AMT‑130 Phase I/II data are insufficient as primary evidence for a marketing application — underscores how quickly regulatory comments can swing valuation. Read More.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure's pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington's disease, and Parkinson's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.